EU Policymakers to Discuss Ashwagandha Regulation Amidst India's Leaf Ban
European Parliament to review ashwagandha regulation on 14 July 2026, driven by industry concerns and India's recent advisory restricting leaf use in food products. Manufacturers face potential reformulation requirements and market access shifts.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
European policymakers will convene on 14 July 2026 at the European Parliament to discuss the regulatory future of ashwagandha. This meeting follows increasing global scrutiny of the botanical, driven by safety concerns and a lack of harmonised regulatory frameworks. Industry experts are advocating for a science-led, evidence-based approach to avoid disproportionate restrictions on a widely used ingredient.
This European deliberation coincides with significant regulatory shifts in key markets. On 16 April 2026, the Indian government issued an advisory strictly prohibiting the use of ashwagandha leaves – whether crude, extract, or any other form – in food products. This unexpected move by the ingredient's country of origin has created immediate compliance challenges for Indian manufacturers and those importing ashwagandha leaf derivatives from the region.
Kerry Group, a major ingredient supplier, has launched a 'Safeguard Ashwagandha' platform to counteract misinformation and provide scientific backing for the botanical's safety. Their recent research, concluded in April 2026, indicates that Sensoril ashwagandha root and leaf extract were safe at doses up to 4,000 mg/kg/day. This data aims to reassure regulators, but the prevailing cautious sentiment suggests brands using leaf extracts could still face market access issues if European authorities align with India's precautionary stance.
The current lack of a unified global approach to ashwagandha regulation creates significant uncertainty for manufacturers and brand owners operating across multiple territories. Discrepancies between national interpretations of safety data and the classification of specific plant parts (root vs. leaf) directly impact product development, sourcing strategies, and market expansion plans.
What this means for United Kingdom
UK brand owners must closely monitor the 14 July 2026 EU Parliament discussions, as subsequent EU decisions often influence MHRA and FSA guidelines. Brands currently utilising ashwagandha leaf extracts or whole plant preparations should initiate risk assessments for reformulation to solely root-based extracts. Procurement leads must evaluate supply chain dependencies on Indian-sourced leaf material, anticipating potential shortfalls and sourcing shifts. Competitive advantage may accrue to brands demonstrating robust scientific safety dossiers for their specific ashwagandha ingredients, particularly those focusing on well-established root extracts. Compliance teams should prepare for updated novel food assessments or specific ingredient restrictions within the next 12-18 months.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.